ASCO launches TAPUR trial
The American Society of Clinical Oncology launched the Targeted Agent and Profiling Utilization Registry (TAPUR) trial, a study of off-label uses of targeted therapies. TAPUR will collect real world clinical outcomes data on off-label use of molecularly targeted cancer drugs, including anti-tumor activity and toxicity. It will study the use of biomarkers to guide off-label use of drugs to treat tumors with known genomic variations, including solid tumors, multiple myeloma (MM) and B cell non-Hodgkin's lymphoma (NHL). The study will include patients who no longer respond to standard-of-care and patients for whom no acceptable treatment is available (see BioCentury, Dec. 22, 2014).
AstraZeneca plc (LSE:AZN; NYSE:AZN), Bristol-Myers Squibb Co. (NYSE:BMY), Eli Lilly and Co. (NYSE:LLY), the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), and Pfizer Inc. (NYSE:PFE) will participate in TAPUR and contribute free drugs. The study will include at least 13 drugs targeting more than 15 genomic variants, and will use data platforms from Syapse Inc. (Palo Alto, Calif.) and Illumina Inc. (NASDAQ:ILMN). ...